MIM
TPTX

MetLife Investment Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

MetLife Investment Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,791
Closed -$1.79M – 2874
2022
Q2 		$1.79M Sell
23,791
-1,747
-7% -$77.6K 0.01% 942
2022
Q1 		$686K Buy
25,538
+9,050
+55% +$304K ﹤0.01% 1575
2021
Q4 		$786K Hold
16,488
– – 0.01% 1241
2021
Q3 		$1.1M Hold
16,488
– – 0.01% 1076
2021
Q2 		$1.29M Buy
16,488
+2,103
+15% +$155K 0.01% 1045
2021
Q1 		$1.36M Sell
14,385
-875
-6% -$104K 0.01% 996
2020
Q4 		$1.86M Buy
15,260
+857
+6% +$93.9K 0.02% 864
2020
Q3 		$1.26M Buy
14,403
+2,289
+19% +$159K 0.01% 930
2020
Q2 		$782K Hold
12,114
– – 0.01% 1134
2020
Q1 		$541K Hold
12,114
– – 0.01% 1177
2019
Q4 		$755K Buy
12,114
+7,718
+176% +$367K 0.01% 1239
2019
Q3 		$165K Hold
4,396
– – ﹤0.01% 2051
2019
Q2 		$179K Buy
+4,396
New +$157K ﹤0.01% 2096

MetLife Investment Management's TPTX Position: Q3 2022 in Review

MetLife Investment Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 23,791 shares — an estimated $1.79M sold.

MetLife Investment Management first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $1.86M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • MetLife Investment Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • MetLife Investment Management sold 23,791 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.79M.
  • MetLife Investment Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • MetLife Investment Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.86M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on MetLife Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.